Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents.
- 1 October 1980
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 77 (10), 5928-5932
- https://doi.org/10.1073/pnas.77.10.5928
Abstract
Treatment of human fibroblast FS-4 cultures with human type II interferon preparations induced the synthesis of at least 4 proteins that were similar in size to 4 of the 5 proteins induced by type I interferons (MW 20,000, 88,000, 67,000 and 56,000). The 67,000 and 56,000 MW proteins were induced more strongly by type II than by type I interferon, and a counterpart of a 80,000 MW protein induced by type I interferons was not noticeably induced by type II interferon preparations. Therefore type I and type II interferons were compared for relative antiviral activities against different viruses (vesicular stomatitis, encephalomyocarditis, vaccinia and reovirus) and for cell growth-inhibitory activities on various cell types. The replication of vesicular stomatitis and encephalomyocarditis viruses were inhibited more strongly by type I interferon; reovirus and vaccinia virus showed greater sensitivity to type II interferon preparations. This indicates that viruses may differ in their sensitivity to human type I and type II interferons and that the antiviral mechanisms induced by type I and type II interferons may have significant differences. The type I and type II interferons may also differ in their efficacies as antiproliferative agents. Type II interferon preparations at 2.5 U/ml inhibited the incorporation of [3H]thymidine to a greater extent than did type I interferon at 400 U/ml. (For both type I and type II interferons, the U of interferon activity was defined as the concentration that decreased the yield of vesicular stomatitis virus by 50% in FS-4 cultures.) Whereas type II interferon preparations had a reversible cytostatic effect on normal human fibroblasts at 10 U/ml, the transformed cells tested (HeLa [cervical carcinoma], osteosarcoma, U-amnion) showed extensive cell death, thus indicating that it may have a cytocidal effect on certain tumor cells. Human type II interferon (or a factor present in these preparations) may be a potent antitumor agent.This publication has 37 references indexed in Scilit:
- Production, partial purification and characterization of human and murine interferons—Type IIMolecular Immunology, 1980
- Human Fibroblast Interferon: Amino Acid Analysis and Amino Terminal Amino Acid SequenceScience, 1980
- Interferon action: induction of specific proteins in mouse and human cells by homologous interferons.Proceedings of the National Academy of Sciences of the United States of America, 1979
- Characteristics of Immune Interferon Produced by Human Lymphocyte Cultures Compared to Other Human InterferonsThe Journal of Immunology, 1975
- A Restriction Point for Control of Normal Animal Cell ProliferationProceedings of the National Academy of Sciences, 1974
- A protein synthesizing system from interferon-treated cells that discriminates between cellular and viral messenger RNAsVirology, 1974
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- Inhibition of Interferon Action by PuromycinThe Journal of Immunology, 1965
- Effect of actinomycin D and puromycin dihydrochloride on action of interferonVirology, 1964
- Inhibition of interferon action by actinomycinBiochemical and Biophysical Research Communications, 1964